Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:31 pm Sale |
2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 4,173,216 6.400% |
-794,898 (-16.00%) |
Filing History |
| 2024-10-28 6:08 pm Purchase |
2024-10-28 | 13D | Tectonic Therapeutic, Inc. TECX |
Atlas Venture Fund X L.P. | 67,567 0.500% |
67,567 (New Position) |
Filing History |
| 2024-04-01 9:52 pm Purchase |
2024-03-25 | 13D | Q32 Bio Inc. QTTB |
Atlas Venture Fund X L.P. | 864,261 7.200% |
864,261 (New Position) |
Filing History |
| 2024-02-09 4:05 pm Unchanged |
2023-12-31 | 13G | Generation Bio Co. GBIO |
Atlas Venture Fund X L.P. | 7,111,939 10.800% |
0 (Unchanged) |
Filing History |
| 2024-02-09 4:03 pm Sale |
2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 4,968,114 8.400% |
-98,811 (-1.95%) |
Filing History |
| 2024-01-25 4:38 pm Sale |
2024-01-23 | 13D | Disc Medicine, Inc. IRON |
Atlas Venture Fund X L.P. | 1,402,186 5.800% |
-191,599 (-12.02%) |
Filing History |
| 2023-09-21 4:44 pm Purchase |
2023-08-15 | 13D | Disc Medicine, Inc. IRON |
Atlas Venture Fund X L.P. | 1,593,785 7.000% |
1,593,785 (New Position) |
Filing History |
| 2023-09-15 4:56 pm Purchase |
2023-09-11 | 13D | Dianthus Therapeutics, Inc. DNTH |
Atlas Venture Fund X L.P. | 186,089 1.300% |
186,089 (New Position) |
Filing History |
| 2023-02-14 4:28 pm Sale |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 5,066,925 9.200% |
-696,087 (-12.08%) |
Filing History |
| 2023-02-14 4:14 pm Purchase |
2022-12-29 | 13D | Gemini Therapeutics, Inc. GMTX |
Atlas Venture Fund X L.P. | 2,237,303 12.900% |
1,835,799 (+457.23%) |
Filing History |
| 2022-12-06 5:00 pm Sale |
2022-11-23 | 13D | Replimune Group, Inc. REPL |
Atlas Venture Fund X L.P. | 1,498,635 3.000% |
-665,402 (-30.75%) |
Filing History |
| 2022-09-14 5:06 pm Sale |
2022-09-12 | 13D | Replimune Group, Inc. REPL |
Atlas Venture Fund X L.P. | 2,164,037 4.400% |
-360,829 (-14.29%) |
Filing History |
| 2022-05-05 4:01 pm Sale |
2021-04-13 | 13D | Magenta Therapeutics, Inc. MGTA |
Atlas Venture Fund X L.P. | 2,977,448 5.100% |
-379,892 (-11.32%) |
Filing History |
| 2022-02-11 5:12 pm Purchase |
2021-03-30 | 13D | Ikena Oncology, Inc. IKNA |
Atlas Venture Fund X L.P. | 2,901,609 8.100% |
2,901,609 (New Position) |
Filing History |
| 2022-02-11 5:09 pm Sale |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 5,763,012 11.200% |
-2,185,970 (-27.50%) |
Filing History |
| 2022-02-11 5:06 pm Sale |
2021-12-31 | 13G | Generation Bio Co. GBIO |
Atlas Venture Fund X L.P. | 7,111,939 12.500% |
-3,000,000 (-29.67%) |
Filing History |
| 2021-02-17 08:26 am Sale |
2021-02-11 | 13D | Magenta Therapeutics, Inc. MGTA |
Atlas Venture Fund X L.P. | 3,357,340 7.000% |
-759,785 (-18.45%) |
Filing History |
| 2021-02-16 5:29 pm Unchanged |
2021-02-12 | 13D | Spero Therapeutics, Inc. SPRO |
Atlas Venture Fund X L.P. | 1,031,160 3.800% |
0 (Unchanged) |
Filing History |
| 2021-02-16 5:28 pm Purchase |
2020-12-31 | 13G | Generation Bio Co. GBIO |
Atlas Venture Fund X L.P. | 10,111,939 21.700% |
10,111,939 (New Position) |
Filing History |
| 2021-02-16 5:27 pm Purchase |
2020-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 7,948,982 17.900% |
7,948,982 (New Position) |
Filing History |